Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 8/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8979378 | 0.92 | HCAR3 (0.56) | GSTM2PRSS1KAT2BTHRBHPGD | |
| SCHEMBL7059270 | 0.89 | HPGD (0.62) | GSTM2PRSS1THRBHPGDL3MBTL1 | |
| SCHEMBL8979405 | 0.89 | HPGD (0.62) | GSTM2PRSS1THRBHPGDL3MBTL1 | |
| SCHEMBL8979398 | 0.86 | THRB (0.48) | GSTM2PRSS1KAT2BTHRBHPGD | |
| SCHEMBL7061507 | 0.86 | GSTM2 (0.43) | GSTM2PRSS1KAT2BHCAR3MAPT | |
| SCHEMBL8813201 | 0.85 | HCAR3 (0.55) | GSTM2KAT2BHCAR3MAPTPOLB | |
| SCHEMBL6854742 | 0.80 | FOLH1 (0.44) | GSTM2PRSS1THRBHPGDL3MBTL1 | |
| SCHEMBL8720435 | 0.77 | ALDH1A1 (0.52) | THRBHPGDL3MBTL1HCAR3MAPT | |
| SCHEMBL8869597 | 0.76 | KAT2B (0.49) | GSTM2PRSS1KAT2BTHRBHPGD | |
| SCHEMBL8868809 | 0.75 | HPGD (0.58) | PRSS1KAT2BTHRBHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780414-B2 | METHODS OF IDENTIFYING BACTERIAL GENES THAT ARE INCOMPATIBLE WITH BACTERIAL PATHOGENICITY, AND THE USE OF SUCH GENES, SUCH AS CADA, TO REDUCE PATHOGENICITY IN A BACTERIA OR TO COMBAT PATHOGENIC BACTERIAL INFECTIONS | HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2004-08-24 | — | — | US | disclosed |
| US-20020192225-A1 | Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-19 | — | — | US | disclosed |
| US-6344201-B1 | INHIBITORS OF E. COLI AND SHIGELLA ENTEROTOXINS; USED FOR DRUGS AND DNA VACCINES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-02-05 | — | — | US | disclosed |